This overexpression was associated with resistance to specific chemotherapies in the ACC cell lines, suggesting the importance of assessing ABC transporter expression by RNA-seq in ACC patient samples, in which case alternative therapeutic strategies should be considered (Supplementary Fig. S1). This evidence concerns the gene ABCG2 and adrenal cortex carcinoma.